ELISA/assay

Human Proto-oncogene serine/threonine-protein kinase pim-1, PIM1 ELISA Kit

MBS701210

48-Strip-Wells

510 USD

ELISA Kit

Human Proto-oncogene serine/threonine-protein kinase pim-1, PIM1 ELISA Kit

pim-1 oncogene

Human Proto-oncogene serine/threonine-protein kinase pim-1 (PIM1) ELISA kit; PIM; Oncogene PIM1; non-specific serine/threonine protein kinase; pim-1 kinase 44 kDa isoform; pim-1 oncogene (proviral integration site 1) ; pim-1 oncogene

serine/threonine-protein kinase pim-1 isoform 1; Serine/threonine-protein kinase pim-1; serine/threonine-protein kinase pim-1; Oncogene PIM1; pim-1 kinase 44 kDa isoform; pim-1 oncogene (proviral integration site 1); proto-oncogene serine/threonine-protein kinase pim-1; Pim-1 proto-oncogene, serine/threonine kinase

PIM1

PIM1; PIM1; PIM

PIM1_HUMAN

Human

404

This assay has high sensitivity and excellent specificity for detection of Human PIM1. No significant cross-reactivity or interference between Human PIM1 and analogues was observed.

Unopened test kits should be stored at 2 to 8 degree C upon receipt. Please refer to pdf manual for further storage instructions.

Samples: Serum, plasma, tissue homogenates, cell culture supernates. Assay Type: Sandwich. Detection Range: 0.312 ng/ml -20 ng/ml. Sensitivity: 0.078 ng/ml

Intra-assay Precision: Intra-assay Precision (Precision within an assay): CV% is less than 8%. Three samples of known concentration were tested twenty times on one plate to assess. Inter-assay Precision (Precision between assays): CV% is less than 10%. Three samples of known concentration were tested in twenty assays to assess. Detection Wavelength: 450 nm. Sample Volume: 50-100ul. Protein Biological Process 1: Apoptosis/Autophagy. Protein Biological Process 3: Apoptosis

Principle of the Assay: This assay employs the quantitative sandwich enzyme immunoassay technique. Antibody specific for PIM1 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any PIM1 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for PIM1 is added to the wells. After washing, avidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of PIM1 bound in the initial step. The color development is stopped and the intensity of the color is measured.

342307046

NP_001230115.1

NM_001243186.1

P11309

45,412 Da

Acute Myeloid Leukemia Pathway (83117); Acute Myeloid Leukemia Pathway (529); C-MYB Transcription Factor Network Pathway (138073); IL-5 Signaling Pathway (198770); Jak-STAT Signaling Pathway (83077); Jak-STAT Signaling Pathway (488); MicroRNAs In Cancer Pathway (852705); MicroRNAs In Cancer Pathway (852928); Role Of Calcineurin-dependent NFAT Signaling In Lymphocytes Pathway (137953); Validated Targets Of C-MYC Transcriptional Activation Pathway (169351)

The protein encoded by this gene belongs to the Ser/Thr protein kinase family, and PIM subfamily. This gene is expressed primarily in B-lymphoid and myeloid cell lines, and is overexpressed in hematopoietic malignancies and in prostate cancer. It plays a role in signal transduction in blood cells, contributing to both cell proliferation and survival, and thus provides a selective advantage in tumorigenesis. Both the human and orthologous mouse genes have been reported to encode two isoforms (with preferential cellular localization) resulting from the use of alternative in-frame translation initiation codons, the upstream non-AUG (CUG) and downstream AUG codons (PMIDs:16186805, 1825810).[provided by RefSeq, Aug 2011]

Function: Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post-translational levels. Phosphorylation of CDKN1B,induces 14-3-3-proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis.7 PublicationsManual assertion based on experiment in:Ref.11. Catalytic activity: ATP + a protein = ADP + a phosphoprotein.3 PublicationsManual assertion based on experiment in:Ref.21. Cofactor: Magnesium.3 PublicationsManual assertion based on experiment in:Ref.21

48-Strip-Wells

510 USD

96-Strip-Wells

725

5x96-Strip-Wells

2565

10x96-Strip-Wells

4800